Mottola Frank's Form 4 filing
Supernus Pharmaceuticals, Inc. (SUPN) · filed Aug 14, 2026
- Accession no.
- 0001804567-26-000014
- Filed
- Aug 14, 2026, 5:10 PM ET
- Trade date
- Aug 12, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mottola FrankCIK 0001804567 | Officer (SVP, Chief Tech. Ops. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Common Stock | MOption exerciseAcquired | +1,650 | $0.00 | $0 | 20,341 | Direct | |
| Aug 12, 2026 | Common Stock | FTax withholdingDisposed | −797 | $46.57 | −$37,116.29 | 19,544 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Common Stock | MOption exerciseDisposed | −1,650 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.